Grant Award View - GA30211
Targeting Cell Death Pathways in Malignant Mesothelioma
Malignant mesothelioma (MM) is an aggressive and incurable cancer with median patient survival of 12 months. By screening a panel of MM cell lines against a new class of drugs that directly target the natural cell death mechanisms in tumour cells, we identified two specific 'survival factors' in MM. Co-targeting of these molecules leads to potent MM cell killing. The proposed research will expand these studies into animal model of MM and potentially provide new treatment options for MM patients.